Bill > S1634

This bill, the "FREED of Opioids Act FDA Review of Efficacy of EERW Double-Blinds of Opioids Act," requires the Food and Drug Administration (FDA) to convene a meeting of its advisory committees within 2 years to vote on whether to permit the use of the enriched enrollment randomized withdrawal (EERW) methodology in clinical trials of drugs, including opioids. The bill also requires the FDA to commission a study by the National Academy of Sciences on the effectiveness of EERW in demonstrating the efficacy of opioid drugs in treating chronic pain, and to consider the findings of that study in its review of the EERW methodology.